Get the Stockscreener App
4.76
9.17%
0.40
Abeona Therapeutics Inc stock is traded at $4.76, with a volume of 976.73K.
It is up +9.17% in the last 24 hours and down -12.98% over the past month.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
See More
Previous Close:
$4.36
Open:
$4.39
24h Volume:
976.73K
Relative Volume:
0.71
Market Cap:
$272.20M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
4.7734
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
-4.03%
1M Performance:
-12.98%
6M Performance:
-11.85%
1Y Performance:
-13.92%
1-Day Range:
$4.35
$4.785
1-Week Range:
$4.28
$5.04
52-Week Range:
$4.00
$7.65
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.76 | 272.20M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
508.13 | 128.79B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
798.88 | 82.25B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.25 | 53.66B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-26 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - GlobeNewswire Inc.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Two new hires' awards cover up to 7,200 Abeona shares, which become theirs over three years if they stay. - Stock Titan
Form 4 Abeona Therapeutics Inc For: 29 September By Investing.com - Investing.com South Africa
Form 4 Abeona Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Abeona Therapeutics CEO Seshadri sells $101,091 in shares By Investing.com - Investing.com South Africa
Abeona Therapeutics CFO Joseph Vazzano sells $47,385 in company stock - Investing.com
Abeona Therapeutics CEO Seshadri sells $101,091 in shares - Investing.com
Abeona Therapeutics CFO Joseph Vazzano sells $47,385 in company stock By Investing.com - Investing.com South Africa
Abeona Therapeutics SVP sells $34,681 in company stock By Investing.com - Investing.com South Africa
Abeona Therapeutics SVP sells $34,681 in company stock - Investing.com
Abeona Therapeutics CCO Madhav sells $25,272 in stock - Investing.com
Abeona Therapeutics CCO Madhav sells $25,272 in stock By Investing.com - Investing.com Canada
To cover stock-award taxes, Abeona Therapeutics (ABEO) CFO sells 9,191 shares. - Stock Titan
To cover stock-award taxes, Abeona Therapeutics (ABEO) legal chief sold 6,727 shares. - Stock Titan
To cover stock-award taxes, Abeona Therapeutics (ABEO) CEO sells 19,608 shares. - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - GlobeNewswire Inc.
To cover taxes on vested stock, an Abeona Therapeutics (ABEO) officer lists shares valued at $47,385 for sale. - Stock Titan
Tax coverage after share vesting: an Abeona Therapeutics (ABEO) officer lists 19,608 shares for sale. - Stock Titan
Tax-related share sale: Abeona Therapeutics (ABEO) lists an officer’s shares for sale at a $34,682 value - Stock Titan
Abeona Therapeutics (NasdaqCM:ABEO) Stock Forecast & Analyst Predictions - Simply Wall Street
Abeona Therapeutics (NASDAQ: ABEO) posts new deck for H.C. Wainwright conference - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - PR Newswire
Abeona at Cantor healthcare conference: slow launch, big rare-disease bet - Investing.com Canada
Abeona at Cantor healthcare conference: slow launch, big rare-disease bet - Investing.com
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - FinancialContent
Don't Ignore The Insider Selling In Abeona Therapeutics - simplywall.st
Responsive Playbooks and the ABEO Inflection - Stock Traders Daily
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Australia
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Canada
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Nigeria
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com India
Abeona Therapeutics director Mark Alvino sells $87,966 in shares - Investing.com
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com UK
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - kdhnews.com
Director Mark Alvino Sells 15,000 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) director sells 15,000 shares, still holds 62,065 - Stock Titan
Director plans Abeona (NASDAQ: ABEO) stock sale from equity awards - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics faces securities fraud prob... - Pluang
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona (ABEO) Stock: Gains 2.18% to Reach $6.09 in the Latest Reading; Range Check: the Supplied Trading Band Runs From $5.79 to $6.39 for the Current SessionCatalyst Driven Stocks - vinanet.vn
High Insider Ownership Growth Stocks To Watch In August 2026 - simplywall.st
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone - Yahoo Finance
Abeona (ABEO) Latest Quarter: EPS Misses Its Estimate in the Latest Session; Market Reaction: The Market Price Declines 2.77% for the Current SessionRevenue Growth Outlook - vinanet.vn
Abeona (ABEO) Q2 2026 Earnings Call Transcript - AOL.com
Abeona (ABEO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abeona Therapeutics Inc Stock (ABEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | Officer |
Sep 29 '26 |
Proposed Sale |
5.16 |
19,608 |
101,091 |
0 |
| Vazzano Joseph Walter | Officer |
Sep 29 '26 |
Proposed Sale |
5.16 |
9,191 |
47,385 |
0 |
| Vasanthavada Madhav | Chief Commercial Officer |
Sep 29 '26 |
Sale |
5.16 |
4,902 |
25,273 |
285,721 |
| O'Malley Brendan M. | SVP, Chief Legal Officer |
Sep 29 '26 |
Sale |
5.16 |
6,727 |
34,682 |
421,226 |
| Vazzano Joseph Walter | Chief Financial Officer |
Sep 29 '26 |
Sale |
5.16 |
9,191 |
47,385 |
482,888 |
| O'Malley Brendan M. | Officer |
Sep 29 '26 |
Proposed Sale |
5.16 |
6,727 |
34,682 |
0 |
| Vasanthavada Madhav | Officer |
Sep 29 '26 |
Proposed Sale |
5.16 |
4,902 |
25,273 |
0 |
| Alvino Mark | Director |
Sep 01 '26 |
Proposed Sale |
5.86 |
15,000 |
87,966 |
0 |
| Alvino Mark | Director |
Sep 01 '26 |
Sale |
5.86 |
15,000 |
87,966 |
62,065 |
| Vazzano Joseph Walter | Chief Financial Officer |
Jul 21 '26 |
Sale |
6.53 |
1,478 |
9,651 |
492,079 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):